BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines.
Slightly overvalued with limited growth.
Share Price & News
How has BioCryst Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BO1's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: BO1 underperformed the German Biotechs industry which returned 7.2% over the past year.
Return vs Market: BO1 underperformed the German Market which returned 14.1% over the past year.
Price Volatility Vs. Market
How volatile is BioCryst Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is BioCryst Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: BO1 (€2.76) is trading below our estimate of fair value (€44.96)
Significantly Below Fair Value: BO1 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: BO1 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: BO1 is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BO1's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BO1 has negative assets, so we can't compare its PB Ratio to the DE Biotechs industry average.
How is BioCryst Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BO1 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BO1 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BO1 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BO1's revenue (48.7% per year) is forecast to grow faster than the German market (5% per year).
High Growth Revenue: BO1's revenue (48.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BO1's Return on Equity is forecast to be high in 3 years time
How has BioCryst Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BO1 is currently unprofitable.
Growing Profit Margin: BO1 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BO1 is unprofitable, and losses have increased over the past 5 years at a rate of -24.5% per year.
Accelerating Growth: Unable to compare BO1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BO1 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: BO1's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Return on Assets
Return on Capital Employed
How is BioCryst Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: BO1 has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: BO1 has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: BO1 has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: BO1's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Inventory Level: BO1 has a low level of unsold assets or inventory.
Debt Coverage by Assets: BO1 has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BO1 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: BO1 has less than a year of cash runway if free cash flow continues to reduce at historical rates of -25.5% each year
What is BioCryst Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BO1's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate BO1's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BO1's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BO1's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BO1's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jon Stonehouse (58yo)
Mr. Jon P. Stonehouse has been the Chief Executive Officer and Executive Director of BioCryst Pharmaceuticals, Inc. at Shionogi & Co., Ltd. since joining in January 8, 2007 and also has been its President ...
CEO Compensation Analysis
Compensation vs Market: Jon's total compensation ($USD4.17M) is above average for companies of similar size in the German market ($USD799.44K).
Compensation vs Earnings: Jon's compensation has increased whilst the company is unprofitable.
|CEO, President & Director||13.1yrs||US$4.17m||0.51% $2.1m|
|CFO, Senior VP & Treasurer||8.6yrs||US$1.80m||0.081% $339.1k|
|Chief Medical Officer & Senior VP||11.6yrs||US$2.35m||0.0027% $11.5k|
|Senior Vice President of Drug Discovery||6.3yrs||US$1.76m||0.10% $421.5k|
|Executive Director of Finance & Principal Accounting Officer||0.08yrs||no data||0.00055% $2.3k|
|Senior Vice President of Investor Relations & Corporate Communications||0yrs||no data||no data|
|Senior VP||13.6yrs||US$1.33m||0.066% $276.5k|
|Vice President of Human Resources||0yrs||no data||no data|
|Senior Vice President of Regulatory Affairs||0yrs||no data||no data|
|Chief Business Officer||0.6yrs||no data||0.029% $121.9k|
Experienced Management: BO1's management team is seasoned and experienced (8.6 years average tenure).
|CEO, President & Director||13.1yrs||US$4.17m||0.51% $2.1m|
|Independent Director||1.1yrs||no data||0.015% $63.5k|
|Independent Chairman||2.8yrs||US$213.41k||0.035% $148.1k|
|Independent Director||8.7yrs||US$200.91k||0.0099% $41.3k|
|Independent Director||8.3yrs||US$180.91k||0.0065% $27.1k|
|Director||0.4yrs||no data||no data|
|Independent Director||1.2yrs||US$193.27k||0.0055% $22.8k|
|Independent Director||8.1yrs||US$190.91k||0.037% $153.2k|
Experienced Board: BO1's board of directors are considered experienced (5.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.8%.
BioCryst Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: BioCryst Pharmaceuticals, Inc.
- Ticker: BO1
- Exchange: DB
- Founded: 1986
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$450.623m
- Listing Market Cap: US$417.412m
- Shares outstanding: 154.06m
- Website: https://www.biocryst.com
Number of Employees
- BioCryst Pharmaceuticals, Inc.
- 4505 Emperor Boulevard
- Suite 200
- North Carolina
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|BCRX||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Mar 1994|
|BO1||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Mar 1994|
|BCRX *||BMV (Bolsa Mexicana de Valores)||Yes||Common Stock||MX||MXN||Mar 1994|
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma. It is also developing BCX7353, an oral serine protease inhibitor and oral dose formulation that is in Phase III clinical trials to treat hereditary angioedema; BCX9930, an oral factor D inhibitor, which is in Phase I clinical trials for mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors that is in preclinical trials to treat fibrodysplasia ossificans progressive; and Galidesivir, an RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trials to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/19 22:07|
|End of Day Share Price||2020/02/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.